Pfizer Q1 FY21 results (Apr–Jun 2020) and concall

Pfizer India delivered a resilient performance in Q1 FY21 despite significant COVID-19 headwinds. While the hospital and pediatric vaccine segments were severely impacted by lockdowns, the core Internal Medicine portfolio grew strongly following a successful sales model restructuring. Exceptional cost control and tax benefits led to double-digit profit growth despite a revenue contraction.